Combination therapy with gemcitabine and nab‑paclitaxel for locally advanced unresectable pancreatic cancer

Saito,Takeshi; Ishido,Keinosuke; Kudo,Daisuke; Kimura,Norihisa; Wakiya,Taiichi; Nakayama,Yoshihito; Hakamada,Kenichi

doi:10.3892/mco.2017.1251

Combination therapy with gemcitabine and nab‑paclitaxel for locally advanced unresectable pancreatic cancer

Authors:
- Takeshi Saito
- Keinosuke Ishido
- Daisuke Kudo
- Norihisa Kimura
- Taiichi Wakiya
- Yoshihito Nakayama
- Kenichi Hakamada
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan
Published online on: May 8, 2017 https://doi.org/10.3892/mco.2017.1251
Pages: 963-967

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the early treatment outcomes of combined gemcitabine and nab‑paclitaxel treatment for locally advanced unresectable pancreatic cancer (LURPC). The subjects comprised 7 patients with LURPC receiving the abovementioned combination therapy at the Hirosaki University Hospital (Hirosaki, Japan) between January and September, 2015. The clinicopathological factors, adverse events and response to treatment were investigated. To determine whether the cases were unresectable, the National Comprehensive Cancer Network guidelines, version 2. 201,) were applied. The patients underwent a median of 4 (range, 2‑7) courses of treatment. The response to treatment was evaluated using the Response Evaluation Criteria In Solid Tumors. The subjects included 1 male and 6 female LURPC patients, with a median age of 71 years (range, 59‑78 years). The tumor was located in the head and body of the pancreas in 6 and 1 patients, respectively. No patients achieved a complete response, 5 achieved a partial response, 2 had stable disease, and none exhibited progressive disease. The response rate was 71%. The mean tumor diameter decreased significantly from 35 mm (range, 24‑60 mm) prior to treatment to 22 mm (range, 20‑35 mm) following treatment. Two patients were downstaged. The mean carbohydrate antigen (CA) 19‑9 values decreased significantly from 767 U/ml (range, 14‑1,977 U/ml) prior to treatment to 35 U/ml (range, 14‑123 U/ml) following treatment. Adverse events classified as grade ≥3 occurred in 4 patients (57%): 3 patients (43%) suffered from neutropenia and 1 patient (14%) developed bilateral cellulitis of the lower extremities. No patients experienced an increase in disease severity, and all were able to continue treatment following temporary withdrawal or dosage reduction. Therefore, combined treatment with gemcitabine and nab‑paclitaxel had favorable tumor‑reducing effects and was not associated with severe adverse events, suggesting that this is a useful therapeutic strategy for patients with LURPC.

View Figures

View References

1	Statistics and Information Department: Vital statistics 2014. Tokyo: Ministry of Health, Labor and Welfare. 2014.http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei14/index.htmlDecember 20–2016
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen JN, Dias LE, et al: FOLFIRINOX in locally advanced pancreatic cancer: The massachusetts general hospital cancer center experience. Oncologist. 18:543–548. 2013. View Article : Google Scholar : PubMed/NCBI
4	Philip PA: Locally advanced pancreatic cancer: Where should we go from here? J Clin Oncol. 29:4066–4068. 2011. View Article : Google Scholar : PubMed/NCBI
5	Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar : PubMed/NCBI
6	von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
7	National Comprehensive Cancer Network, . NCCN clinical practic guideline in oncology: Pancreatic adenocarcinoma. Fort Washington, PA: National Comprehensive Cancer Network, Version; 2. pp. 222015
8	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
9	Nakayama N, Ishido K, Chin K, Nishimura K, Azuma M, Matsusaka S, Inokuchi Y, Tanabe S, Kumekawa Y and Koizumi W: A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. Gastric Cancer. 20:350–357. 2017. View Article : Google Scholar : PubMed/NCBI
10	Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
11	Rizvi NA, Riely GJ, Azzoli CG, Miller VA, Ng KK, Fiore J, Chia G, Brower M, Heelan R, Hawkins MJ and Kris MG: Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol. 26:639–643. 2008. View Article : Google Scholar : PubMed/NCBI
12	Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, et al: Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 109:926–933. 2013. View Article : Google Scholar : PubMed/NCBI
13	Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI and Tuveson DA: nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2:260–269. 2012. View Article : Google Scholar : PubMed/NCBI
14	Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y, Nakajima TE and Furuse J: Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 77:595–603. 2016. View Article : Google Scholar : PubMed/NCBI
15	Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S, Weitz J, Werner J, Schirmacher P, et al: Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol. 7:282012. View Article : Google Scholar : PubMed/NCBI
16	Nanda RH, El-Rayes B, Maithel SK and Landry J: Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 111:1028–1034. 2015. View Article : Google Scholar : PubMed/NCBI
17	Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, et al: Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 22:1153–1159. 2015. View Article : Google Scholar : PubMed/NCBI
18	Chen Y, Sun XJ, Jiang TH and Mao AW: Combined radiochemotherapy in patients with locally advanced pancreatic cancer: A meta-analysis. World J Gastroenterol. 19:7461–7471. 2013. View Article : Google Scholar : PubMed/NCBI
19	Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 19:1592–1599. 2008. View Article : Google Scholar : PubMed/NCBI
20	Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR and Benson AB III: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial. J Clin Oncol. 29:4105–4112. 2011. View Article : Google Scholar : PubMed/NCBI
21	Kim R and Salf MW: Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP. 8:279–288. 2007.PubMed/NCBI
22	Conroy T, Paillot B, François E, Bugat R, Jacob JH, Stein U, Nasca S, Metges JP, Rixe O, Michel P, et al: Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol. 23:1228–1236. 2005. View Article : Google Scholar : PubMed/NCBI
23	Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, et al: Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 31:23–29. 2013. View Article : Google Scholar : PubMed/NCBI
24	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
25	Satoi S, Yamaue H, Kato K, Takahashi S, Hirono S, Takeda S, Eguchi H, Sho M, Wada K, Shinchi H, et al: Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments: Results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 20:590–600. 2013. View Article : Google Scholar : PubMed/NCBI